Results 111 to 120 of about 105,114 (279)

Achievement of the Ideal Outcome After Pancreatectomy for Pancreatic Ductal Adenocarcinoma Is Associated With Earlier Initiation and Higher Completion Rates of Adjuvant Chemotherapy and Improved Long‐Term Survival

Annals of Gastroenterological Surgery, EarlyView.
ABSTRACT Background The Ideal Outcome is a composite quality indicator reflecting optimal postoperative course after pancreatic surgery. This study aimed to clarify the prognostic significance of achieving the Ideal Outcome and its influence on the initiation and completion of adjuvant chemotherapy.
Ryosuke Fukushima, Kenichiro Araki, Ryo Muranushi, Kouki Hoshino, Kei Hagiwara, Shunsuke Kawai, Mariko Tsukagoshi, Takamichi Igarashi, Norio Kubo, Ken Shirabe   +9 more
wiley   +1 more source

H‑Gemcitabine: A New Gemcitabine Prodrug for Treating Cancer

, 2016
In this report, we present a new strategy for targeting chemotherapeutics to tumors, based on targeting extracellular DNA. A gemcitabine prodrug was synthesized, termed H-gemcitabine, which is composed of Hoechst conjugated to gemcitabine.
Abhinav P. Acharya (2002042), Seungjun Lee (2000281), Dongin Kim (2002045), Sungmun Lee (534990), Niren Murthy (1320648), Madhuri Dasari (2002039), Ross Molinaro (138224), Jeanne Rhea (2002036)   +7 more
core   +1 more source

CD86‐Positive Mature Tertiary Lymphoid Structures Are Associated With CD8+ T‐Cell Infiltration and Favorable Clinical Outcomes in Pancreatic Ductal Adenocarcinoma

Annals of Gastroenterological Surgery, EarlyView.
CD86‐positive mature tertiary lymphoid structures were associated with increased intratumoral CD8+ T‐cell infiltration, a higher proportion of Granzyme B‐expressing CD8+ T cells in an exploratory analysis, and favorable clinical outcomes in pancreatic ductal adenocarcinoma.
Takaomi Seki, Kenichiro Araki, Takehiko Yokobori, Hayato Ikota, Norio Kubo, Takamichi Igarashi, Mariko Tsukagoshi, Norihiro Ishii, Yasuo Hosouchi, Hiroshi Saeki, Ken Shirabe   +10 more
wiley   +1 more source

Conditions causing gemcitabine crystallization

, 2011
Introduction. Intravesical delivery of chemotherapy agents is used very commonly for the treatment of superficial bladder cancer. We recently completed a phase II study of intravesical gemcitabine in which an alkaline adjusted gemcitabine preparation was
Manners, Susan, Galettis, Peter, Souza, Paul de (R16678)   +2 more
core   +2 more sources

Synthesis of Gemcitabine-Threonine Amide Prodrug Effective on Pancreatic Cancer Cells with Improved Pharmacokinetic Properties

Molecules, 2018
To investigate the amino acid transporter-based prodrug anticancer strategy further, several amino acid-conjugated amide gemcitabine prodrugs were synthesized to target amino acid transporters in pancreatic cancer cells. The structures of the synthesized
Sungwoo Hong, Zhenghuan Fang, Hoi-Yun Jung, Jin-Ha Yoon, Soon-Sun Hong, Han-Joo Maeng   +5 more
doaj   +1 more source

Antitumor effect of gemcitabine-loaded albumin nanoparticle on gemcitabine-resistant pancreatic cancer induced by low hENT1 expression

, 2018
Zhongyi Guo,1 Feng Wang,2 Yang Di,1 Lie Yao,1 Xinzhe Yu,1 Deliang Fu,3 Ji Li,3 Chen Jin1 1Department of Pancreatic Surgery, Huashan Hospital, Fudan University, Shanghai, China; 2School of Pharmacy & Key Laboratory of Smart Drug Delivery, Fudan ...
Yao L, Li J, Guo ZY, Jin C, Wang F, Fu DL, Yu XZ, Di Y   +7 more
core  

Zebrafish xenograft models as a fast platform for metastasis diagnosis and cisplatin response of head and neck squamous cell carcinoma

Animal Models and Experimental Medicine, EarlyView.
A zebrafish xenograft model accurately distinguishes metastatic from non‐metastatic HNSCC and recapitulates cisplatin sensitivity/resistance patterns. Using patient‐derived tumors, it predicts individual therapeutic responses, offering a rapid, clinically applicable platform for guiding personalized treatment. Abstract Background Head and neck squamous
Lu Chen, Shu Sun, Yujia Liu, Liehao Jiang, Cuiyun Wu, Ting Liu, Yujiao Zhao, Yuwei Liu, Lu Liu, Qi Wang, Xiaowei Zheng, Ping Huang   +11 more
wiley   +1 more source

Pharmacogenomic profiling of the efficacy of gemcitabine monotherapy in metastatic pancreatic cancer: Subgroup analysis of the GENESECT study

British Journal of Clinical Pharmacology, EarlyView.
Aim In the GENESECT study, no significant gemcitabine (GEM) metabolism‐related germline genetic polymorphisms (GPs) were identified because approximately 70% of patients received combination therapy with nab‐paclitaxel, which has metabolic pathways different from GEM.
Takashi Yokokawa, Daiki Tsuji, Masahiro Hatori, Kazuyoshi Kawakami, Masahiko Nakao, Takuya Yano, Yuichiro Arakawa, Keisuke Matsuo, Yasukata Ohashi, Masato Ozaka, Naoki Sasahira, Yasuhiko Sakata, Yuki Kogure, Shinya Tamaki, Atsushi Wada, Yusuke Taki, Wataru Suzuki, Kazuo Kobayashi, Hiroshi Ishii, Kunihiko Itoh, Masakazu Yamaguchi, Kenichi Suzuki   +21 more
wiley   +1 more source

From pathogen to “living drug factory” innovative strategies and clinical translation of bacteria as programmable intelligent vectors for cancer therapy

BMEMat, EarlyView.
Engineered bacteria serve as smart, living therapeutics that target tumors, deliver drugs, and remodel immunosuppressive microenvironments. This review highlights their potential to potentiate immunotherapy, radiotherapy, and chemotherapy, offering a promising paradigm for precise and synergistic cancer treatment. Abstract The dynamic interplay between
Haonan Shen, Weichen Zhang, Gaoli Niu, Li Wang, Ruiyan Li, Yueyue Fan, Feixue Lu, Lingling Xu, Xiaoyuan Ji, Yong Kang   +9 more
wiley   +1 more source

CUB domain-containing protein 1 signaling dysregulates gemcitabine metabolism contributing to therapeutic resistance in T24 cells.

PLoS ONE
Gemcitabine is commonly used in the standard first-line treatment of urothelial carcinoma (UC); however, the emergence of drug resistance significantly limits its clinical benefit.
Kun-Lin Hsieh, Kuan-Hua Huang, Ching-Ping Chang, Hung-Wen Tsai, Yu-Hao Chang, Yi-Ru Zheng, Huei-Sheng Huang   +6 more
doaj   +1 more source